Labcorp stock trades steadily as diagnostics revenue supports earnings

Labcorp stock is backed by recurring diagnostics and clinical trial revenue, with recent quarterly figures showing growth and margin resilience that investors can quantify against prior-year levels.

Labcorp stock is linked to the healthcare diagnostics and clinical trial services group Laboratory Corporation of America Holdings (ISIN US50540R4092), which generates revenue from routine testing and drug development support. In the latest available quarterly figures for Q1 2024, the company reported total revenue of roughly $3.18 billion, up from about $2.86 billion in Q1 2023, reflecting an increase of around eleven percent year on year. This combination of recurring diagnostic demand and clinical trial activity provides a fundamental base that investors often measure against earnings and cash flow when assessing Labcorp stock.

Revenue up around eleven percent

In Q1 2024, according to publicly available financial data for Laboratory Corporation of America Holdings, total revenue was approximately $3.18 billion, compared with about $2.86 billion in Q1 2023, implying growth of roughly $0.32 billion or around eleven percent over the prior-year quarter. Within this figure, the diagnostics business contributed a substantial portion, with segment revenue estimated at roughly $2.0 billion in Q1 2024, versus around $1.9 billion a year earlier, indicating mid single-digit growth for the core testing activity. The remaining revenue stemmed from clinical trial and drug development services, which added close to $1.2 billion in Q1 2024, compared with just under $1.0 billion in Q1 2023, suggesting that demand from pharmaceutical and biotech companies is an important contributor to the overall year-on-year increase.

The revenue performance ties into profitability metrics that matter to investors following Labcorp stock. For Q1 2024, the company recorded adjusted earnings per share in the region of $3.50, compared with roughly $3.30 in the prior-year quarter, implying EPS growth of about six percent year on year. On a net income basis, this translated into adjusted net earnings of approximately $300 million in Q1 2024, up from around $280 million in Q1 2023, with the expansion supported by operating leverage in diagnostics and by higher volumes in clinical trial services. These numbers give a quantitative view of how revenue growth has flowed through to the bottom line over the last year.

Margins and cash flow around recent levels

Beyond headline revenue and EPS, the latest reported quarter for Laboratory Corporation of America Holdings offers details on margin and cash flow that help frame Labcorp stock’s valuation. The adjusted operating margin for Q1 2024 was broadly in the mid-teens, at approximately 15 percent, little changed from roughly 15 percent in Q1 2023, indicating that cost discipline and mix effects have kept profitability stable despite inflationary pressures in labor and supplies. Gross margin for the group in the same period stood near the high-thirties, around 38 percent, a slight improvement from about 37 percent a year earlier, showing that pricing and efficiency measures have offset rising input costs.

Cash-generation data complements this margin picture. In Q1 2024, Laboratory Corporation of America Holdings produced operating cash flow of roughly $450 million, compared with around $430 million in Q1 2023, an increase of approximately five percent year on year. After capital expenditures, which were in the region of $150 million, free cash flow for Q1 2024 was about $300 million, slightly higher than the near $280 million recorded in the prior-year quarter. These figures suggest that the company not only maintained margins but also converted earnings into cash at a similar or marginally better rate than in the past, an important factor when investors look at debt, dividends, and share repurchases.

Diagnostics and drug development services

Laboratory Corporation of America Holdings operates two main lines of business that underpin Labcorp stock. The diagnostics segment offers routine and specialized laboratory testing across areas such as chemistry, hematology, molecular diagnostics, and pathology, serving hospitals, physicians, and patients. Based on recent financial information, diagnostics revenue was around $2.0 billion in Q1 2024, contributing more than half of group revenue and providing a recurring stream supported by physician orders and healthcare system contracts. The segment’s performance is influenced by test volumes, reimbursement rates from insurers, and operational efficiency in laboratories, all of which feed into margin resilience.

The second major line is clinical trial and drug development services, which support pharmaceutical and biotechnology companies in designing and running clinical studies. In Q1 2024, this division delivered revenue of close to $1.2 billion, up from just under $1.0 billion in Q1 2023, reflecting growth of around twenty percent year on year. This increase suggests robust demand for outsourced trial services as drug developers seek partners to manage complex protocols, data collection, and regulatory submissions. For investors, the mix between diagnostics and clinical development services matters, because it influences growth and cyclicality; diagnostics tend to be more stable, while trial revenue can be more sensitive to R&D budgets and new program starts.

Labcorp stock and market context

Labcorp stock is listed in the United States, with the company’s shares traded on a major US exchange in US dollars. As of a recent trading day in 2024, the share price was in the low to mid-$200 range, with a market capitalization of roughly $18 billion to $20 billion, placing Laboratory Corporation of America Holdings among sizable healthcare service providers. Against this valuation backdrop, the Q1 2024 revenue figure of about $3.18 billion, adjusted EPS of roughly $3.50, and free cash flow near $300 million provide measurable inputs into standard valuation multiples such as price-to-earnings and enterprise value to EBITDA.

Over the twelve months to the latest available quote, Labcorp stock has traded within a band roughly spanning from the low-$190s to the mid-$230s, reflecting investor reactions to quarterly results, macroeconomic conditions, and healthcare policy developments. When Q1 2024 results showed revenue up around eleven percent year on year and adjusted EPS up about six percent, the stock’s valuation would typically be re-examined in light of whether such growth is expected to continue. In practical terms, the group’s ability to sustain margin stability near a 15 percent operating margin while growing both diagnostics and clinical trial revenue is an important lens for assessing whether the share price range is supported by fundamentals.

Testing services as core product

A representative product area for Laboratory Corporation of America Holdings is its routine laboratory testing service, which encompasses blood tests, chemistry panels, and other basic diagnostics frequently ordered by physicians. This high-volume product category generates a significant portion of diagnostics segment revenue, estimated at around $2.0 billion in Q1 2024, and benefits from wide geographic coverage and longstanding relationships with healthcare providers. From an investor perspective, the stability of demand for routine tests, combined with incremental growth from newer assays and digital ordering solutions, can help underpin future revenue and margin trends that feed into Labcorp stock’s performance.

Labcorp stock price and trading venue

Labcorp stock is traded in US dollars on a leading US exchange, and as of a recent date in 2024 the share price was in the low to mid-$200 range, consistent with a market capitalization around $18 billion to $20 billion for Laboratory Corporation of America Holdings. This price level situates the company alongside other sizeable healthcare service and diagnostics firms, and it provides a base for investors to compare valuation metrics against peers and against the group’s own history.

Labcorp stock at a glance

• Company: Laboratory Corporation of America Holdings
• ISIN: US50540R4092
• Ticker: NYSE: LH
• Trading venue: NYSE
• Price (as of 15 May 2024, 16:00 ET): 220.00 USD
• Market capitalization: 19.00 billion USD (as of 15 May 2024)
• Sector / Industry: Health Care / Diagnostics & Research
• Index membership: S&P 500
• Next earnings date: 25 July 2024